Standard BioTools and Hims & Hers Health Compared

Which medical company stock is the better investment?

Apr. 19, 2026 at 2:19pm by

Got story updates? Submit your updates here. ›

An extreme close-up photograph of complex, interlocking medical machinery and instruments, conveying the technical sophistication of the healthcare technology industry.A detailed look at the intricate machinery powering the next generation of medical innovation.San Francisco Today

Standard BioTools (NASDAQ:LAB) and Hims & Hers Health (NYSE:HIMS) are both medical companies, but which is the superior stock? This analysis contrasts the two companies based on factors like institutional ownership, dividends, profitability, and valuation to determine which is the better investment option.

Why it matters

Investors looking to gain exposure to the medical technology and telehealth sectors need to understand the key differences between these two companies to make an informed decision about which stock to add to their portfolio.

The details

Standard BioTools and Hims & Hers Health have different business models, with Standard BioTools focused on analytical instruments and Hims & Hers Health operating a telehealth platform. The analysis looks at metrics like revenue, earnings, price-to-earnings ratio, institutional ownership, and analyst recommendations to assess the relative strengths of each company.

  • The analysis was published on April 19, 2026.

The players

Standard BioTools

A medical technology company that provides analytical instruments, consumables, reagents, and software services for researchers and clinical laboratories.

Hims & Hers Health

A telehealth company that connects consumers to healthcare professionals for mental health, sexual health, dermatology, and primary care services.

Got photos? Submit your photos here. ›

The takeaway

Investors will need to weigh the relative strengths and weaknesses of Standard BioTools and Hims & Hers Health to determine which stock better fits their investment objectives and risk tolerance. The analysis highlights the key differences between the two companies that should inform that decision.